These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35136230)

  • 21. Approvals in 2022: overall survival, dose optimization, new approvals and beyond.
    Telaraja D; Gormley N; Pazdur R
    Nat Rev Clin Oncol; 2023 Apr; 20(4):207-208. PubMed ID: 36823362
    [No Abstract]   [Full Text] [Related]  

  • 22. Conflicting signals on US accelerated approvals.
    Fox JL
    Nat Biotechnol; 2005 Sep; 23(9):1027-8. PubMed ID: 16151377
    [No Abstract]   [Full Text] [Related]  

  • 23. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
    Olivier T; Haslam A; Prasad V
    JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond fast track for drug approvals.
    Roberts TG; Chabner BA
    N Engl J Med; 2004 Jul; 351(5):501-5. PubMed ID: 15282359
    [No Abstract]   [Full Text] [Related]  

  • 25. Significant FDA approvals in 1999.
    McGinnis TJ
    Am Fam Physician; 2000 Apr; 61(8):2531-3. PubMed ID: 10794586
    [No Abstract]   [Full Text] [Related]  

  • 26. The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another.
    Tao D; Schott S; Prasad V
    Am J Med; 2019 Mar; 132(3):e509-e511. PubMed ID: 30201241
    [No Abstract]   [Full Text] [Related]  

  • 27. New Approvals in Cancer Treatment.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749878
    [No Abstract]   [Full Text] [Related]  

  • 28. Recent and anticipated novel drug approvals for 2024.
    Rim MH; Karas BL; Barada F; Levitsky AM
    Am J Health Syst Pharm; 2024 May; 81(10):385-389. PubMed ID: 38373160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drug approvals in 2001.
    Wynn RL
    Gen Dent; 2002; 50(4):304-8, 310. PubMed ID: 12640845
    [No Abstract]   [Full Text] [Related]  

  • 30. Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals.
    Lammers A; Wang R; Cetnar J; Prasad V
    Blood Cancer J; 2017 Nov; 7(12):637. PubMed ID: 29187747
    [No Abstract]   [Full Text] [Related]  

  • 31. Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.
    Blumenthal GM; Pazdur R
    Nat Rev Clin Oncol; 2019 Mar; 16(3):139-141. PubMed ID: 30670830
    [No Abstract]   [Full Text] [Related]  

  • 32. New drug approvals in 2002.
    Wynn RL
    Gen Dent; 2003; 51(3):212-6. PubMed ID: 15055702
    [No Abstract]   [Full Text] [Related]  

  • 33. Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.
    Zhou J; Vallejo J; Kluetz P; Pazdur R; Kim T; Keegan P; Farrell A; Beaver JA; Sridhara R
    J Natl Cancer Inst; 2019 May; 111(5):449-458. PubMed ID: 30085269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2022 FDA approvals.
    Mullard A
    Nat Rev Drug Discov; 2023 Feb; 22(2):83-88. PubMed ID: 36596858
    [No Abstract]   [Full Text] [Related]  

  • 35. Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
    Donaldson JM; Seddiq M; Fusco MJ; Singla S; Pamuk GE; Lee-Alonso RJ; Mixter BD; Goldberg KB; Amiri-Kordestani L; de Claro RA; Drezner N; Gormley NJ; Kanapuru B; Lemery SJ; Fashoyin-Aje LA; Richardson NC; Singh H; Suzman DL; Theoret MR; Kluetz PG; Pazdur R
    Cancer Discov; 2023 Dec; 13(12):2515-2524. PubMed ID: 38084090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2023 FDA approvals.
    Mullard A
    Nat Rev Drug Discov; 2024 Feb; 23(2):88-95. PubMed ID: 38168801
    [No Abstract]   [Full Text] [Related]  

  • 37. Recent biotechnology approvals.
    Piascik P
    J Am Pharm Assoc (Wash); 2000; 40(3):433-4. PubMed ID: 10853546
    [No Abstract]   [Full Text] [Related]  

  • 38. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.
    Hilal T; Gonzalez-Velez M; Prasad V
    JAMA Intern Med; 2020 Aug; 180(8):1108-1115. PubMed ID: 32539071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New drugs and product approvals from 2001.
    Taylor SE
    Tex Dent J; 2002 Dec; 119(12):1186-98. PubMed ID: 12592740
    [No Abstract]   [Full Text] [Related]  

  • 40. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.